Innate Pharma Gross Profit

The latest gross profit for IPHA is $14M as of June 2026. That compares with $-14M in the prior-year period — up 197.7% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Innate Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, IPHA's gross profit moved from $-14M to $14M — a 197.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Innate Pharma's operating scale or balance-sheet position.

Against Healthcare companies, IPHA currently prints $14M for gross profit, while the sector average sits near $65B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Innate Pharma's growth, margins, and balance sheet.

A gross profit figure of $14M for IPHA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting IPHA's gross profit ($14M), review year-over-year change from $-14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.